# A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

> **NCT00480935** · PHASE2 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 3 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Sunitinib Malate (Sutent)

## Key facts

- **NCT ID:** NCT00480935
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** poor recruitment
- **Last updated:** 2015-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00480935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00480935, "A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00480935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*